Abstract:Notably, the manuscript delineates how formoterol shifts MoMFs from a pro‐inflammatory M1 phenotype to a reparative M2 phenotype, a process mediated by increased glutaminase activity. This mechanism highlights a novel aspect of macrophage function regulation, which could be pivotal for developing new treatments for VMC. Furthermore, our results suggest that targeting β2‐AR could be an effective approach to manage and treat VMC, presenting a significant step forward in the pharmacological management of this disease. Background Viral myocarditis (VMC) plays a significant role in heart failure, and there is currently a shortage of available targeted treatments. Macrophage phenotype and function are closely associated with the beta‐2 adrenergic receptor (β2‐AR). Method This research employed a BALB/c mouse model of VMC generated using Coxsackievirus B3 (CVB3), and the β2‐AR agonist formoterol was administered as treatment. A bioinformatic analysis was conducted to identify the β2‐AR in CCR2+MHCIIhigh monocyte‐derived macrophages (MoMFs). Echocardiography and histopathological assessments were utilized to evaluate cardiac function and inflammation. The enzymatic activity of glutaminase (GLS) was quantified. Flow cytometry was employed to characterize the phenotype and function of the macrophages. Result Our study revealed that formoterol treatment effectively mitigated cardiac inflammation and fibrosis, improved cardiac function, and prolonged survival compared to the VMC group. Formoterol reduced the infiltration of CCR2+MHCIIhigh MoMFs in the heart, inhibited M1 phenotypic expression and activity, and reduced the percentage of Ly6Chigh monocytes in circulation. Additionally, formoterol stimulated M2 phenotypic expression and activity and increased the percentage of Ly6Clow monocytes in circulation. Additionally, the combination of NICB3344, a C‐C motif chemokine receptor 2 inhibitor, with formoterol did not exhibit synergistic effects on reducing cardiac pathological scores or enhancing cardiac function. In vitro studies involving the use of lipopolysaccharide (LPS)‐induced bone marrow‐derived macrophages, revealed the ability of formoterol to suppress the M1 phenotype and functions induced by LPS while promoting the M2 phenotype and functions. Nevertheless, the observed effects were negated by the introduction of the GLS inhibitor BPTES. Conclusion Formoterol potentially serves as a significant metabolic regulator in the differentiation process of cardiac MoMFs, influencing this process by controlling GLS activity. Targeting β2‐AR exhibits potential as an effective approach for managing VMC. It is essential to acknowledge that these findings were derived under specific experimental conditions, with the current conclusions predominantly based on animal models. Future research is necessary to further investigate the feasibility of formoterol in clinical practice.

Multitargeted Immunomodulatory Therapy for Viral Myocarditis by Engineered Extracellular Vesicles

Targeted immunomodulation therapy for cardiac repair by platelet membrane engineering extracellular vesicles via hitching peripheral monocytes

Immunosuppressive microvesicles-mimetic derived from tolerant dendritic cells to target T-lymphocytes for inflammation diseases therapy

M2 Macrophage‐Derived sEV Regulate Pro‐Inflammatory CCR2+ Macrophage Subpopulations to Favor Post‐AMI Cardiac Repair

Surface engineering enhances the therapeutic potential of systemically delivered extracellular vesicles following acute myocardial infarction

Effect of extracellular vesicles derived from inflammatory H9C2 cardiomyocytes on the polarization of macrophages and its mechanism

Reconstituted Extracellular Vesicles from Human Platelets Decrease Viral Myocarditis in Mice

Macrophage-derived VEGF-C reduces cardiac inflammation and prevents heart dysfunction in CVB3-induced viral myocarditis via remodeling cardiac lymphatic vessels

Use of Cationic Microbubbles Targeted to P-selectin to Improve Ultrasound-Mediated Gene Transfection of Hvegf165 to the Ischemic Myocardium

Dpep2 Emerging As a Modulator of Macrophage Inflammation Confers Protection Against CVB3-Induced Viral Myocarditis

Engineering extracellular vesicles with platelet membranes fusion enhanced targeted therapeutic angiogenesis in a mouse model of myocardial ischemia reperfusion

Injection‐Free Delivery of MSC‐Derived Extracellular Vesicles for Myocardial Infarction Therapeutics

Limiting Cardiac Ischemic Injury by Pharmacological Augmentation of Macrophage Migration Inhibitory Factor–AMP-Activated Protein Kinase Signal Transduction

Formoterol Reduces the Pro‐Inflammatory Phenotype by Enhancing the Activity of Glutaminase in Monocyte‐Derived Macrophages in the CVB3‐Induced Viral Myocarditis

Genetically Engineered Macrophages Co-Loaded with CD47 Inhibitors Synergistically Reconstruct Efferocytosis and Improve Cardiac Remodeling Post Myocardial Ischemia Reperfusion Injury

Engineered M2 macrophage-derived extracellular vesicles with platelet membrane fusion for targeted therapy of atherosclerosis

M2 macrophage exosome-derived lncRNA AK083884 protects mice from CVB3-induced viral myocarditis through regulating PKM2/HIF-1α axis mediated metabolic reprogramming of macrophages

Mononuclear phagocyte system blockade using extracellular vesicles modified with CD47 on membrane surface for myocardial infarction reperfusion injury treatment

AIM2 Co-Immunization Favors Specific Multifunctional CD8+ T Cell Induction and Ameliorates Coxsackievirus B3-induced Chronic Myocarditis

MicroRNA-30a-5p silencing polarizes macrophages toward M2 phenotype to alleviate cardiac injury following viral myocarditis by targeting SOCS1

Atorvastatin-pretreated mesenchymal stem cell-derived extracellular vesicles promote cardiac repair after myocardial infarction via shifting macrophage polarization by targeting microRNA-139-3p/Stat1 pathway